PFS
ESPR

Prospera Financial Services’s Esperion Therapeutics ESPR Stock Holding History

Prospera Financial Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-203
Closed -$1K – 1899
2022
Q1 		$1K Buy
+203
New +$871 ﹤0.01% 2598
2020
Q4 		– Sell
-203
Closed -$8K – 921
2020
Q3 		$8K Buy
+203
New +$8.04K ﹤0.01% 1166

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Prospera Financial Services's ESPR Position: Q2 2022 in Review

Prospera Financial Services sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 203 shares — an estimated $1K sold.

Prospera Financial Services first reported a position in ESPR in Q3 2020 and held it in 2 quarters. The position peaked at $8K in Q3 2020. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

  • Prospera Financial Services reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 203 Esperion Therapeutics shares in Q2 2022, an estimated $1K.
  • Prospera Financial Services first reported a position in Esperion Therapeutics in Q3 2020 and held it in 2 quarters.
  • Prospera Financial Services's Esperion Therapeutics position peaked at $8K in Q3 2020.
  • 136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.